Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy
Shintaro Narita(Akita University), Tomonori Habuchi(Akita University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Kyoko Nomura(Akita University), Kengo Nagashima(Keio University Hospital), Norihiko Tsuchiya(Yamagata University), Jiro Shimoda(Iwate Prefectural Central Hospital), Shigeto Ishidoya(Sendai City Hospital), Koji Mitsuzuka(Pacific Northwest Diabetes Research Institute), Senji Hoshi, Chikara Οhyama(Hirosaki University), Yoichi Arai(Japan Atomic Energy Agency), Toshihiko Sakurai(Sojo University), Masahiro Takahashi(Tohoku University), Hiromi Sato(Akita University), Shingo Hatakeyama(Hirosaki University), Masanori Ishida(Iwate Prefectural Central Hospital), Tatsuo Tochigi(Miyagi Prefectural Hospital Organization), Toshiaki Kawaguchi(Aomori Prefectural Central Hospital)
Cited by 6
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial
|Journal of Clinical Oncology|2013|253